UNCY NASDAQ
Unicycive Therapeutics, Inc.
1W: -5.0%
1M: -22.2%
3M: -23.8%
YTD: -37.8%
1Y: -29.6%
3Y: -58.5%
5Y: -85.8%
$3.61
+0.03 (+0.84%)
Weekly Expected Move ±8.7%
$3
$4
$4
$4
$5
Credit Risk of going bust: lower than 62% of companies Debt: 0.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down 99.9%), Unicycive Therapeutics, Inc. would be worth roughly what it owes.
Total debt $671K against a stock market value of $98.9M.
Distance to default 6.39 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $336K (short-term plus half of long-term), stock volatility 84.4%; Altman Z'' -1.95. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down 99.9%), Unicycive Therapeutics, Inc. would be worth roughly what it owes.
Total debt $671K against a stock market value of $98.9M.
Distance to default 6.39 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $336K (short-term plus half of long-term), stock volatility 84.4%; Altman Z'' -1.95. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
4 relationships4
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2022-07-18
Earliest Filing
2024-07-02
Latest Filing
partner: 2
supplier: 1
licensee: 1
Counterparties (Filed by UNCY)
4 relationshipsCompanies named in UNCY's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Shilpa Medicare, Ltd. | — | supplier | Supplier of oxylanthanum carbonate (OLC) tablets and manufacturing services under a Manufacturing and Supply Agreement. | 2024-07-02 | View |
| EF Hutton | — | partner | Placement Agent for the Series A-1 Convertible Preferred Stock offering | 2023-03-06 | View |
| Benchmark Investments, LLC | — | partner | Parent entity of EF Hutton acting as Placement Agent | 2023-03-06 | View |
| Lee's Pharmaceutical (HK) Limited | — | licensee | Exclusive license agreement for Renazorb in Mainland China, Hong Kong, and certain other Asia markets. | 2022-07-18 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-29 | Officer/Director Change; Other Events; Exhibits | View | |
| 2026-09-28 | Other Events | View | |
| 2026-08-12 | Earnings Release; Exhibits | View | |
| 2026-07-02 | Other Events | View | |
| 2026-06-22 | Shareholder Vote | View | |
| 2026-06-05 | Material Agreement; Exhibits | Agreement | View |
| 2026-05-12 | Earnings Release; Exhibits | View | |
| 2026-04-06 | Officer/Director Change | View | |
| 2026-03-30 | Earnings Release; Exhibits | View | |
| 2025-11-14 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-28 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2025-08-18 | Other Events | View | |
| 2025-08-15 | Other Events | View | |
| 2025-08-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-08 | Other Events; Financial Statements and Exhibits | View | |
| 2025-06-30 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2025-06-20 | Material Modification to Rights of Security Holders; Amendments to Articles of Incorporation or Byla | View | |
| 2025-06-10 | Other Events; Financial Statements and Exhibits | View | |
| 2025-06-09 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR